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Tobacco smoking is known to impact circulating levels of major immune cells populations,
but its effect on specific immune cell subsets remains poorly understood. Here, using
high-resolution data from 223 healthy women (25 current and 198 never smokers), we
investigated the association between smoking status and 35,651 immune traits capturing
immune cell subset frequencies. Our results confirmed that active tobacco smoking
is associated with increased frequencies of circulating CD8+ T cells expressing the
CD25 activation marker. Moreover, we identified novel associations between smoking
status and relative abundances of CD8+ CD25+memory T cells, CD8+memory T cells
expressing the CCR4 chemokine receptor, and CD4+CD8+ (double-positive) CD25+
T cells. We also observed, in current smokers, a decrease in the relative frequencies of
CD4+ T cells expressing the CD38 activation marker and an increase in class-switched
memory B cell isotypes IgA, IgG, and IgE. Finally, using data from 135 former female
smokers, we showed that the relative frequencies of immune traits associated with active
smoking are usually completely restored after smoking cessation, with the exception
of subsets of CD8+ and CD8+ memory T cells, which persist partially altered. Our
results are consistent with previous findings and provide further evidence on how tobacco
smoking shapes leukocyte cell subsets proportion toward chronic inflammation.
Keywords: tobacco smoking exposure, immune traits, leukocyte-shift, immune cell subset frequencies,
epidemiology
INTRODUCTION
According to the 2019 World Health Organization report, tobacco smoking kills more than eight
million people every year (1), and its association with the development of several pathologies, such
as respiratory, cardiovascular, neurological, and autoimmune diseases, as well as of several types of
cancer, is well established (2–4).
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In healthy individuals, tobacco smoking alters leukocyte
cells count and distribution in peripheral blood, with several
studies showing, in both sexes, an increase in the total number
of leukocytes in current smokers compared to former and
never smokers (5–7). The mechanisms underlying this alteration
are not fully understood yet, and studies investigating the
effect of smoking on the immune system led to conflicting
conclusions (8, 9). The leading hypothesis suggests that the
irritating effect of tobacco smoke on the respiratory tract results
in the release of pro-inflammatory cytokines, such as TNF-α,
IL-1, IL-6, IL-8, and granulocyte-macrophage colony-stimulating
factor, which can, in turn, increase the number of leukocytes
(7). Alternatively, it has been suggested that nicotine-induced
release of hormones from the adrenal gland (catecholamines) can
stimulate cortisol secretion and thus inhibit antibody responses,
T cell proliferation, and neutrophilic phagocytic activity (5, 6).
So far, studies have investigated the effect of tobacco smoking
only on primary leukocyte subsets (e.g., T cells, B cells, natural
killer cells, monocytes, and granulocytes), showing a decrease in
circulating natural killer cells (10), an increase of CD3+ (11),
CD4+ (helper) (5, 12), memory and naïve T cells (13) in current
compared to never smokers. A decrease of T-helper cells and
an increase of CD8+ (cytotoxic) T cells, corresponding to a
decreased CD4+/CD8+ ratio, in current compared to never
smokers has also been reported (14), albeit this observation was
then contradicted in another study (15). Yet, a finely detailed
investigation of the effect of smoking on more specific leukocyte
subsets is still lacking.
In this study, using information from 358 females from
the TwinsUK cohort, we investigated: (a) the association
between active tobacco smoking and 35,651 immune traits
capturing immune cell subset frequencies (CSFs) and (b) whether
the relative frequencies of these associated immune traits
show evidence of restoration to non-smoking frequencies after




The TwinsUK cohort includes about 14,000 subjects, with
a large prevalence of women, showing disease and lifestyle
characteristics similar to the general UK population (16, 17).
St. Thomas’ Hospital Research Ethics Committee approved the
study, and all twins provided written informed consent.
Immunophenotyping
A full description of the quantification of the immune cells
and their phenotype is detailed elsewhere (18, 19). Briefly,
leukocytes were characterized in 497 females from the TwinsUK
cohort using cryopreserved PBMC samples. All samples were
analyzed by flow cytometry on seven distinct 14-color panels
(summarized in Supplementary Table 1) with an optimized
staining procedure (18). Molecular markers were purchased from
BectonDickinson, BioLegend, eBiosciences, Life Technologies,
Beckman Coulter, Fisher Scientific, or Miltenyi Biotec; or
conjugated in house. A full description of gating strategy for each
panel is reported in (18), except for panel 6, reported in (19).
In the first stage, parent lineages were defined within each panel
via manual gating based on canonical marker combinations for
leukocyte subsets of known functionality. Within each parent
lineage, boolean gates were then manually defined for each
additional cell surfacemarker (i.e., markers not used to determine
the parent lineage), and information on all combinations of
these boolean gates (i.e., whether positive, negative or ignored)
were subsequently used to define subsets of immune cells and to
measure their immune cell subset frequencies (CSFs, evaluated as
percentages with respect to the total number of leukocytes in their
parent lineage). Using this approach, we captured a grand total
of 88,367 immune traits, describing 50 supersets of the parent
lineages, and 88,317 CSFs.
To select 35,651, robust immune traits, we applied several
criteria. First, we removed 41,336 CSFs with median value <0.1
or >99%, as done previously (18, 19). Second, we removed 34
redundant CSFs which passed the previous quality check steps
and were measured in multiple panels (median Spearman’s ρ
within pairs = 0.88, range = 0.37–0.95). Third, we removed
11,296 CSFs strongly deviating from normality.
Immune traits were log-transformed, to improve the
normality of their distribution, and then corrected for batch
effects using a linear mixed model, as implemented in the R
package lme4 (v1.1.21) with flow cytometry batch number
included as a random effect. Before carrying out the association
analyses, we removed outliers (i.e., immune trait measurements
deviating more than three standard deviations from the mean of
each trait).
Self-Reported Smoking History
Detailed information about smoking history was self-reported
via 11 longitudinal questionnaires, collected from 1992 to 2010
in 496 individuals with immunophenotyping available (median
number of responses: 7). Consistency of self-reported smoking
status was assessed using additional self-reported information,
i.e., age of start and quitting smoking, and the number of
cigarettes and/or packs smoked. For instance, individuals who
described themselves as never smokers, but reported, in any
questionnaire, age of start and/or quitting smoking, and/or
that they had smoked any number of cigarettes were removed
from this study. We allowed for smoking relapse after smoking
cessation and considered as current status the latest reported
before immunophenotyping. This resulted in the inclusion of
460 individuals, 35 of whom were current smokers, 189 former
smokers, and 236 reported never having smoked.
History of immune-mediated inflammatory diseases (IMID,
i.e., chronic obstructive pulmonary disease, Crohn’s disease,
systemic lupus erythematosus, multiples sclerosis, polymyalgia
rheumatica, psoriatic arthritis, rheumatoid arthritis, and
ulcerative colitis) was traced through 15 longitudinal self-
administered questionnaires completed between 2004 and 2017
(median number of responses per individual: 3). For each
condition, study subjects who reported being diagnosed by
a doctor at least once were treated as IMID cases, and when
multiple ages at first diagnosis were provided, the minimum
age was considered. Cancer history was available from the
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FIGURE 1 | Study sample and design. Left panel: criteria used to select the women included in the study. Starting from 496 women with immunophenotyping and
smoking history, 358 subjects were selected to be part of the study, which included 25 current, 135 former, and 198 never smokers. Right panel: analysis design.
First, we aimed at identifying differences in the immune trait relative proportions between current and never smokers. Then, using data from former smokers, we
investigated whether the relative proportion of these significantly different immune traits were fully or partially restored to never-smoker frequencies after smoking
cessation. IMIDs: immune-mediated inflammatory diseases.
2019 Office for National Statistics. Non-melanoma skin cancers
and carcinomas in situ were not taken into account. Using
these pieces of information, 102 individuals were excluded
either because having a diagnosis of IMID reported before or
within 2 years from immunophenotyping or being diagnosed
for one or more cancers dating 5 years before or within 1 year
from immunophenotyping.
The final dataset consisted of 358 healthy female individuals,
25 of whom were current smokers, 135 former smokers, and 198
never smokers (Figure 1, left panel; Supplementary Table 2).
Lifestyle Factors
Height and weight were measured for all individuals included in
this study during twins’ clinical visits at King’s College London.
Individuals were asked to remove their shoes, and height (in
cm) was measured using a stadiometer, while weight (in kg) was
measured on digital scales.
Socioeconomic status was measured using the Index of
Multiple Deprivation (IMD) based on the postcode (or UK grid
reference mapped to postcode) where an individual lived at the
time or near the time of sample collection (20), which was
available for 344 individuals included in this study (24 current,
126 former, and 194 never smokers). IMD values range from 1
(=more deprived) to 5 (=less deprived).
Alcohol consumption was calculated using UK food
composition table from 131-item self-administered food-
frequency questionnaires established for the EPIC-Norfolk
study (21), which were collected within 5 years from
immunophenotyping. It was available for 320 individuals
included in this study (20 current, 123 former, and 177
never smokers).
Statistical Analyses
First, we aimed at identifying the immune traits involved in the
response to active smoking using data from current and never
smokers (Figure 1, right panel). Due to the high variability of
time of smoking cessation before immunophenotyping (range:
1–50 years), we excluded former smokers from this analysis to
avoid any confounding effects. Associations of immune traits
with smoking status were carried out using a linear mixed model,
as implemented in the lmerTest R package (function lmer, v3.1.1),
including age at immunophenotyping as a fixed effect, and family
as a random effect, to correct for the non-independence of the
twin observations.
Due to the strong correlation among immune traits, we
considered as significant the associations passing a Bonferroni-
derived threshold of 0.05/Neff, where Neff is the effective
number of independent tests calculated on the whole set of 497
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individuals with immunophenotyping data using the approach
proposed by Li and Ji (22).
Due to the unequal sample size between current and never
smokers, for each of theN immune traits passing the Bonferroni-
derived threshold of 0.05/Neff described above, we generated
5,000 random datasets where labels indicating smoking status
were randomly permuted between monozygotic/dizygotic twin
pairs and among singletons, in order to preserve the family
structure and, thus, the underlying genetic correlation. Then,
we counted the number of times T the association p-value in
the random datasets was lower than 0.05/Neff, and used this
number to evaluate an empirical p-value as (T + 1)/5,001. We
confirmed an association as significant when its empirical p-
value passed a Bonferroni-derived threshold of 0.05/Meff, where
Meff is the effective number of independent tests evaluated by
the approach proposed by Li and Ji on the subset of the N
significantly associated immune traits.
Then, to rule out the presence of a confounding effect
due to alcohol consumption, we investigated whether alcohol
consumption was associated with the identified immune traits
using the statistical model described above, and considered as
significant associations passing a Bonferroni-derived threshold
of 0.05/Meff.
Next, we investigated whether the immune traits associated
with active smoking remained altered after smoking cessation
using data from former and never smokers and the statistical
model described above (Figure 1, right panel). Finally, to
investigate the presence of a trend in the relative frequencies of
the altered immune traits in current vs. former vs. never smokers,
we performed a further association study including the three
smoking categories (i.e., current, former, and never smokers;
Figure 1, right panel), following the statistical model detailed
above. In both analyses, associations passing a Bonferroni-
derived threshold of 0.05/Meff were considered as significant.
RESULTS
This study included 358 healthy women of European ancestry
(43 and 94 monozygotic and dizygotic twin pairs, respectively,
and 84 singletons) with an average age of 60.9 ± 8.3
years (range: 41–78), 25 (7%), 135 (38%), and 198 (55%)
of whom were current, former, and never smokers at the
time of immunophenotyping, respectively (Figure 1, left panel;
Supplementary Table 2). We observed a significant difference
in alcohol consumption (ANOVA p = 3.9 × 10−4) but not in
age, body mass index, and socioeconomic status distributions
between current, former, and never smokers (ANOVA p >
0.05, Supplementary Table 2). In line with studies showing
heritability of smoking habits (23–25), monozygotic twin pairs
were more likely than dizygotic one to share the same smoking
status (72 vs. 55%, Supplementary Table 3).
Associated immune traits belonging to the same subset were
highly correlated to one another (Supplementary Figures 1–3),
and this correlation was particularly strong among immune traits
presenting similar patterns of molecular markers. This can be
explained by the fact that these traits are hierarchically and
functionally correlated, as they originated from a limited number
of common progenitors. Therefore, to facilitate the description
of the obtained results, we present them as groups of highly
correlated immune traits characterized by at least a common
molecular marker. Mean Pearson’s correlation coefficients are
reported in the text for each group of CSFs. The cell lineages,
subsets, and phenotypic markers used here are defined according
to the nomenclature reported in Roederer et al. (18). Our findings
are summarized in Figure 2.
Frequency of Circulating T Cells, B Cells,
and Monocytes Is Influenced by Active
Smoking
In the proposed analysis design, we firstly compared immune
trait relative proportions in current (n = 25) vs. never (n =
198) smokers (section Materials and Methods; Figure 1, right
panel). We identified 842 (2%) CSFs associated with active
smoking at a Bonferroni-derived threshold of 0.05/2,610 =
1.9 × 10−5, and whose association was further confirmed
by permutation testing (P < 0.05/79 = 6.3 × 10−4, section
Materials and Methods, Supplementary Data 1, Figure 2, left
panel, Figure 3). None of them was significantly associated
with alcohol consumption (P < 0.05/74 = 6.7 × 10−4, section
Materials and Methods, Supplementary Data 2), suggesting that
the identified associations are attributable to active smoking
rather than to the confounding effect of alcohol.
The identified CSFs belonged to the two major lymphocyte
populations of T cells (n= 710, 84% of the total associated CSFs)
and B cells (n = 128, 15%), and to the monocyte lineage (n = 4,
0.5%). Among the T cells, we found 541 (76% of the associated
T cells) CSFs of CD8+, 162 (23%) CSFs of CD4+, 4 (0.6%) CSFs
of CD4+CD8+ double-positive (DP), and 3 (0.4%) CSFs of γδ
T cells subsets. B cell immune traits included 75 (59% of the
associated B cells) CSFs of class-switched memory B cells, 39
(30%) CSFs of plasma cells, 10 (8%) CSFs of transitional, and 4
(3%) CSFs of naïve B cells subsets.
CD8+ T Cells
The largest number of associated CSFs belonged to the CD8+
subset expressing the CD25 activation marker (CD8+CD25+;
280/541, 52% of associated CSFs of CD8+ T cells). More
in detail, 65 CSFs expressed exclusively the CD25 activation
marker with a pro-inflammatory effect (mean Pearson’s |ρ| =
0.90), 52 CSFs expressed CD25 in combination with the CD73
marker with regulatory phenotype and immunosuppressive
capability (CD8+CD25+CD73+; mean Pearson’s |ρ| = 0.94),
and 67 CSFs expressed CD25 and the CD127 marker of
proliferation activity and with a pro-inflammatory effect
(CD8+CD25+CD127+; mean Pearson’s |ρ|= 0.90). The relative
proportions of these immune traits were positively associated
with active smoking (i.e., their relative proportions were
increased in current smokers; Figure 4). Conversely, 4 CSFs
of CD8+ T cells not expressing the CD25 marker (CD25-;
mean Pearson’s |ρ| = 0.94) displayed an opposite direction
of effects (i.e., their relative proportions were decreased in
current smokers; Figure 4). Within the CD8+CD25+ T cell
subsets, we also identified 96 CSFs of CD8+ T cells with
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FIGURE 2 | Effects of tobacco smoking on circulating immune traits. Left panel: immune traits significantly associated with active smoking (current vs. never
smokers). Right panel: immune traits that persist altered after smoking cessation (former vs. never smokers). For each molecular marker or cell-subset, arrows
summarize the direction of association (positive/negative) and the pro-inflammatory (in red) or immunosuppressive (in blue) function. Markers are defined according to
the nomenclature reported in Roederer et al. (18).
memory phenotype (CD8+CD45RO+) positively associated
with active smoking. Of these, 34 CSFs expressed exclusively
the CD25 activation marker (CD8+CD25+CD45RO+; mean
Pearson’s |ρ| = 0.98), 32 CSFs expressed the CD25 and CD73
markers (CD8+CD25+CD73+CD45RO+; mean Pearson’s |ρ|
= 0.99), and 30 expressed the CD25 and CD127 markers
(CD8+CD25+CD127+CD45RO+; mean Pearson’s |ρ|= 0.98).
Additionally, 88 CSFs of CD8+ T cells with memory
phenotype and expressing the CCR4 chemokine
receptor were positively associated with active smoking
(CD8+CD45RO+CCR4+; mean Pearson’s |ρ| = 0.73),
whereas 40 CSFs of CD8+CD45RO+CCR4– were negatively
associated (mean Pearson’s |ρ| = 0.54; Figure 4). We further
identified 12 CSFs of CD8+CD45RO+ T cells expressing
the CD161 activation and pro-inflammatory marker
(CD8+CD45RO+CD161+; mean Pearson’s |ρ| = 0.96)
that were decreased in current compared to never smokers,
and 15 CSFs of central memory T cells (mean Pearson’s |ρ| =
0.78), 10 CSFs of long-term memory T cells (mean Pearson’s
|ρ| = 0.89), and 16 CSFs of transitional memory T cells (mean
Pearson’s |ρ|= 0.89) that were increased in smokers.
Finally, we observed, in current vs. never smokers, a
significant increase in the relative proportions of 17 CSFs of
CD8+ T cells expressing the CD28 activation marker (CD28+;
mean Pearson’s |ρ| = 0.89), 41 expressing the CD127 marker
(CD127+; mean Pearson’s |ρ| = 0.84), and 18 expressing the
CD95 (CD95+, also known as Fas or apoptosis antigen 1) marker
inducing apoptosis (mean Pearson’s |ρ|= 0.85).
CD4+ T Cells
We identified 107 CSFs of CD4+ T cells expressing the CD38
activationmarker with pro-inflammatory activity (CD38+; mean
Pearson’s |ρ| = 0.60) negatively associated with active smoking.
Conversely, the relative proportions of CD4+CD38– were
increased in current smokers (n= 8, mean Pearson’s |ρ|= 1).
We also identified, as negatively associated with active
smoking, a subset of 12 CSFs of T helper-2 (CCR4+, n =
12, mean Pearson’s |ρ| = 0.91), pre-T helper-17 expressing the
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FIGURE 3 | Composition of CSFs associated with active smoking. The bar
chart shows, for each group of presented immune trait, the percentage of
CSFs associated with active smoking (current vs. never smokers) with respect
to the total amount of CSFs analyzed for that group.
CD161 marker (CCR4+ CD161+; n = 24, mean Pearson’s |ρ|
= 0.81), and naïve CD4+ T cells (CD45RA+, n = 11, mean
Pearson’s |ρ|= 0.98).
CD4+CD8+ Double Positive T Cells
The relative proportion of 4 CSFs of DP T cells expressing the
CD25 activation marker (CD4+CD8+CD25+; mean Pearson’s
|ρ|= 0.72) was increased in current vs. never smokers.
γδ T Cells CD45RA+
The relative proportions of 3 CSFs belonging to the γδ T cells
subset (Vg9+Vd2– subset) and expressing the CD45RA naïve
marker (CD45RA+; mean Pearson’s |ρ| = 1) were decreased in
current compared to never smokers.
B Cells
CSFs of class-switched memory B cells isotypes IgA, IgG, and
IgE (CD38–; n = 64, mean Pearson’s |ρ| = 0.66; n = 10, mean
Pearson’s |ρ| = 0.65; and n = 1, respectively) were positively
associated with active smoking. On the contrary, CSFs of B cells
expressing the CD38 marker (CD38+; known as plasma cells; n
= 39, mean Pearson’s |ρ| = 0.37; Figure 4) decreased in current
smokers compared with never smokers.
We further observed 10 immune traits in the transitional
stage of B cells co-expressing the CD21 naïve marker and the
CD95 memory B cells activation marker (CD21+CD95+; mean
Pearson’s |ρ| = 0.85) positively associated, and 4 naïve B cells
(CD21+; mean Pearson’s |ρ| = 1) negatively associated with
active smoking.
Monocytes
We identified 4 CSFs belonging to classical monocytes which
express CD14 and HLA-DR activation marker and were
negatively associated with active smoking (CD14+HLA-DR+;
mean Pearson’s |ρ|= 0.95).
Immune Traits Are Either Completely or
Partially Restored in Former Smokers
In the second part of our analysis, we investigated whether the
842 CSFs previously identified remained significantly different
in former (n = 135) vs. never smokers (n = 198), that is,
whether their relative frequency was restored to non-smoking
level in individuals who quitted smoking (section Materials
and Methods; Figure 1, right panel). Time since smoking
cessation ranged from 1 to 50 years (mean = 22.8, SD = 11.7;
Supplementary Figure 4).
Of the 842 CSF associated with smoking, 385 CSFs (46%) were
not significantly different between former and never smokers (p-
value ≥ 0.05), including the majority of CSFs of B cells (120/128,
94%) and a small proportion of CSFs of CD8+ (91/541, 17 %) T
cells, and all CSFs of CD4+, CD4+CD8+ DP, and γδ T cells as
well as monocyte subsets, suggesting complete restoration after
smoking cessation (Figure 5, Supplementary Data 3).
Conversely, at a Bonferroni-derived threshold of 0.05/74 =
6.8 × 10−4 (section Materials and Methods), 254 (30%) CSFs,
belonging to the CD8+ T cell (254/541, 47%) subsets (further
discussed below) continued to be significantly different in former
compared to never smokers (Supplementary Data 3, Figure 2,
right panel, Figure 5). Interestingly, when the association testing
was performed using the three smoking categories (section
Materials and Methods, Figure 1, right panel), these 254 CSFs
showed significant decreasing effect size from current, to former,
to never smokers, thus suggesting that these CSFs were not
still completely altered but, in fact, partially restored (Figure 5,
Supplementary Data 3).
CD8+ T Cells
We observed that 74% (48/65) of the CSFs of CD8+CD25+
T cells remained significantly altered after smoking
cessation (Figure 5), as were 55% (37/67) of CSFs of
CD8+CD25+CD127+ T cells, 88% (15/17) of the CSFs
CD8+CD28+ T cells, 38% (7/18) CSFs of CD8+CD95+
T cells, and 68% (28/41) CSFs of CD8+CD127+ T cells.
Conversely, the relative proportion of 17% (9/52) of the
CSFs of CD8+CD25+CD73+ T cells, and 50% (2/4) CSFs
of CD8+CD25– T cells were completely restored to never
smoker levels.
Within the CSFs of CD8+ T cells with
memory phenotype, we observed that the relative
proportions of all the CD8+CD25+CD45RO+ and
CD8+CD25+CD127+CD45RO+ CSFs, and of one
CD8+CD25+CD73+CD45RO+ CSF were significantly
different in former vs. never smokers, as were 13% (2/15) CSFs
of central memory T cells, and all the CSFs of long-term memory
T cells and of transitional memory T cells.
CSFs of CD8+CCR4+ and CD8+CCR4– memory T cells
showed amixed behavior: 30% (26/88) of the CSFs expressing the
CCR4 chemokine receptor marker (Figure 5) were still altered
after smoking cessation, while 36% (32/88) and 90% (36/40) of
the CSFs of CD8+CCR4+ and CD8+CCR4– memory T cells
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FIGURE 4 | Distribution of selected CSFs in 223 healthy women. Raw relative proportions are plotted, and each boxplot reports effect size (β), standard error (SE),
and p-value (P) of the linear regression analysis (current vs. never smokers). Opposite directions of effects are shown for a selected set of markers: left column CD25
(25+/25–) marker in CD8+ T cells, middle column CCR4 (CCR4+/CCR4–) chemokine receptor marker in CD8+ memory T cells, right column CD38 (38+/38–)
marker in B cells isotype IgG.
were completely restored – as were all the CSFs of CD8+CD161+
memory T cell.
DISCUSSION
Studies on the effects of tobacco smoking on the immune
system have shown conflicting results, most likely because of
the variability in smoking exposure (i.e., smoking dose and/or
whether cigarettes, pipe, or cigars were smoked) as well as the
intrinsic differences in study populations (e.g., in age, sex, or
ethnicity), and their sample size (9, 26). Moreover, the majority of
these studies focused only on primary leukocyte subpopulations
(i.e., CD3, CD4+, CD8+ T cell, B cell, natural killer cells,
monocytes, and granulocytes) which aremore abundant in blood,
and, consequently, easier to measure (5, 12).
In this study, we explored the association between self-
reported smoking status and 35,651 immune traits measured by
flow cytometry in the peripheral blood of 358 healthy women
of European ancestry. To the best of our knowledge, this is the
first finely detailed study aimed at elucidating the relationship
between smoking and both the innate and adaptive circulating
immune cells.
T Cells
Our study confirmed that active smoking predominantly
changes the relative proportions of circulating leukocytes of
the T cell subsets. For instance, the increase of CD8+CD25+
T cells reported in our study has been previously observed in
the peripheral blood of healthy smokers (27), in the airway
epithelium of smokers with chronic bronchitis (28), and in
the blood of smokers with lung cancer (29). The identified
CD8+CD25+ activated T cells showed a predominance of
the proliferating phenotype (CD127+) but also the presence
of the regulatory phenotype (CD73+). Studies suggested
that CD8+CD25+CD73+ T cell may have an elevate
immunosuppressive capacity, inhibiting the proliferation
of effector T cells (30, 31), thus explaining the observed
pro-inflammatory and immunosuppressive effect of tobacco
smoking (5, 6).
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FIGURE 5 | Distribution of selected CSFs in 333 healthy women. Raw relative proportions are plotted, and each boxplot reports effect size (β), standard error (SE),
and p-value (P) of the linear regression analysis (former vs. never smokers). Relative proportions in current smokers are shown for comparison. Left column: CSFs
partially restored after smoking cessation, central and right columns: CSFs completely restored after smoking cessation.
Here, we also suggest an association between a small number
of CSFs of CD8+CD4+CD25+ DP and of CD8+CD25+
memory T cells and active smoking. While DP T cells are
present only in small number in the peripheral blood of healthy
individuals, their frequency has been previously associated with
several inflammatory and autoimmune diseases (32). In the
healthy human thymus, activated CD25+ DP T cells show
suppressive functions similar to regulatory T cells (33). The
high proportion of CD8+CD25+ memory T cells in smokers
is consistent with their increased proliferation following antigen
recognition due to a systemic inflammation associated with
smoking (34, 35). Taken together, these results suggest that
smoking may increase the activation of CD8+ T cells stimulating
their proliferation, with concomitant activation of CD8+ T
regulatory and DP T cell with immunosuppressive properties.
Consistently with the literature, we also observed a positive
association between active smoking and CD8+ T cells expressing
the CD28 co-stimulatory molecules that play an important
role in the activation of the T-cell-mediated immune response
during the inflammatory processes (36, 37). Active smoking
was also positively associated with CD8+ T cells expressing the
CD95 apoptotic marker, previously reported associated with both
reduced lung functions and hypoxaemia (38).
We also identified a novel positive association between active
smoking and the relative proportion of CD8+ memory T cells
expressing the CCR4 chemokine receptor. While the role of the
CCR4 receptor in CD8+ memory T cells remains unexplored,
studies in animal models showed that cigarette smoking induces
the production of CCR4+ ligands in macrophages and dendritic
cells, which in turn recruit monocytes in the lung (39) and
induce the activation of natural killer cells through the mediation
of the CCR4 receptor (40). These findings indicate that the
CD8+CCR4+ memory T cells may be involved in smoking
response by recruiting CD8+ T cells in inflammatory sites.
We observed an increase of the relative proportion of CSFs
of CD8+ memory T cells, in particular central, transitional,
and long-term memory subsets, and a decrease of CSFs of
T-helper (Th) cells, such as Th2 and pre-Th17T cell subsets
in active smokers. Increase of CD8+ memory T cells and
reduction of Th2 in smokers are in line with previous studies
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indicating a cumulative effect of smoking causing an increase
of memory T cells, as well as an immunosuppressive effect
decreasing Th-2 response (9, 34, 35). The decrease in the relative
proportion of pre-Th17 might be explained by their recruitment
into the inflamed lung tissue, where they will exert their pro-
inflammatory role as mature Th17T cells (41, 42).
Furthermore, we observed a decrease of CSFs of CD4+
T cells expressing the CD38 activation marker. This marker
is preferentially expressed by naïve CD4+ T cells, conferring
a reduced capacity to proliferate and to respond to IL-2
cytokine signaling (43). Interleukin IL-2 carries out homing
regulation and proliferation of T cells (44). We speculate
that smoking-related inflammation increases IL-2 levels in
circulation, promoting the activation of CD8+ T cells, and
decreasing the number of CD4+CD38+ T cells in current
compared to never smokers. This regulation might be due
to an impaired response to IL-2, or the suppressor activity
performed by CD8+ T cells with regulatory phenotype induced
by smoking (31).
The observed decrease in the relative proportions of CSFs
of Vγ9Vδ2 T cells in smokers could be explained by their
preferential recruitment in the lung in response to chronic smoke
exposure, as suggested by a study in mice (45).
Interestingly, when analyzing data from former smokers,
we observed that the relative frequency of CSFs of CD8+ T
cells subsets only displayed a partial restoration to non-smokers
frequency after smoking cessation. In particular, we found
that CSFs of activated CD8+CD25+ T cells, CD8+CD25+
memory T cells, CD8+ T cells expressing the CD28 activation
marker and/or the CD127 proliferation marker, those involved in
apoptotic pathways (CD95+) as well as CSFs of CD8+ memory
T cell expressing the CCR4 chemokine receptor, central memory,
long term memory, and of transitional memory T cells were still
partially altered after smoking cessation. These results suggest
that smoking could persistently alter the phenotypes of the
circulating CD8T cells, and this might reflect permanent damage
in the lung tissue caused by long-term exposure. A recent study
in former smokers highlighted that the decline in lung functions
persists for decades after smoking cessation (46). This decline
is consistent with continuous pathophysiological abnormalities,
including inflammatory, infective, and immunity abnormalities
of the lung in both COPD patients and healthy individuals
(9, 47, 48). Moreover, two studies in broncho-alveolar lavage
fluid of COPD patients who were former smokers showed that
smoking cessation did not prevent the rates of apoptotic T cells
from increasing (49), and, even after 5 years, the percentage of
CD8+CD25+ T cells in former smokers remained increased in
comparison to never smokers (50), further suggesting a persistent
inflammation of the airways after quitting smoking.
Conversely, the relative frequencies of CSFs of T reg
phenotype (CD8+CD25+CD73+) in both CD8+ T cell subsets,
of resting CD8+CD25– T cells, and of CD8+CD161+memory T
cells were completely restored after smoking cessation. Notably,
CSFs of CD8+ memory T cells expressing or not the CCR4
chemokine receptor showed a mixed behavior after smoking
cessation: those CCR4+ were in equal part completely and
partially restored, whilst those CCR4– were almost all completely
restored, and we might speculate that this may be again caused
by permanent smoking-induced lung damage.
A previous study in peripheral blood on 174 healthy
individuals showed that smoking cessation completely restored
CD8+ and CD3+ T cell, B cell, and monocyte proportions
within 1 year, and CD4+ T cells proportion after 2 years (5), as
also observed by other studies which reported either a complete
restoration of absolute white blood cell count after 1 year from
smoking cessation (51) or of lymphocytes and monocytes count
within 2–5 years (52). On the one hand, our results, which show
the complete restoration of several cell-subsets, such as B cells
and monocytes, confirm these observations. On the other hand,
they suggest that the dysregulation of the immune system may
persist, at different degrees in other cell-subsets, such as in CD8+
and CD8+ memory T cells. This highlights the importance
of investigating the effect of smoking also on finely detailed
leukocyte subpopulations, as this may help to explain why the
risk of smoking-related pathologies remains elevated even after
smoking cessation (53).
B Cells
Along with the described modification in T cell relative
proportions, we observed, in current smokers, an increase of the
relative proportions of class-switched memory B cells (IgA, IgG,
and IgE isotypes), and a decrease of the relative proportions of
plasma cells, the latter releasing immunoglobulins in circulation
in response to antigens recognition (54). These findings are in
agreement with what reported in a previous study which showed
an increase of class-switched memory B-cells isotype IgA in
peripheral blood of current smokers compared to former and
never smokers (55). The authors suggested that this increase
may be the result of chronic inflammation due to continued
smoking, and might be associated with the formation or release
of (neo)antigens, such as smoke particles or damaged lung tissue.
They also hypothesized that continued smoking exposure may
cause a secondary immune response, increasing the circulating
class-switched memory B cells and memory B cells formation in
current smokers (55, 56). As already observed (5, 55), the large
majority of CSFs of both class-switched and plasma B cells were
completely restored to never smoker levels after cessation.
Monocytes
Finally, we identified a negative association between active
smoking status andCSFs belonging to themonocyte subset. Their
decreased relative proportions in smokers could be explained by
their preferential recruitment in the lung for generating alveolar
macrophages (35), and was completely restored after smoking
cessation, in agreement with what reported in the literature
(5, 52).
Limitations
We are aware that this study presents some limitations.
First, our study sample included only women of European
ancestry, while the effect of smoking on the immune system
has been shown to differ between males and females (5, 57)
and between European and non-European populations (58).
Second, information on smoking status was self-reported while
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information on second-hand smoking was missing, making it
impossible to exclude residual confounding or misclassification
bias. Third, the limited sample size hindered the investigation of
how the time since smoking cessation influenced the trajectories
of immune trait restoration.
Conclusions
In summary, we detail here how tobacco smoking shapes
leukocyte cell subset proportions in healthy women. The
shift of immune cells composition in peripheral blood caused
by active smoking affects mainly cell-subsets expressing pro-
inflammatory or immunosuppressive molecular markers, rather
than entire cell-subsets, and changes induced by smoking are
not completely reverted even years after smoking cessation.
Further investigations are required to dissect the role of these
immune traits in smoking- and immune-related diseases, such as
autoimmune disorders and cancer.
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